Cargando…

Brain network modulation in Alzheimer’s disease: clinical phenotypes and windows of opportunity

Detalles Bibliográficos
Autor principal:	Pini, Lorenzo
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Wolters Kluwer - Medknow 2022
Materias:	Perspective
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9241393/ https://www.ncbi.nlm.nih.gov/pubmed/35799521 http://dx.doi.org/10.4103/1673-5374.340410

Ejemplares similares

Digital phenotyping: An equal opportunity approach to reducing disparities in Alzheimer's disease and related dementia research
por: Britton, Gabrielle B., et al.
Publicado: (2023)

COVID-19: A Window of Opportunity for Positive Healthcare Reforms
por: Auener, Stefan, et al.
Publicado: (2020)

Response: How to Use a Window of Opportunity
por: Chisolm, Margaret S., et al.
Publicado: (2011)

Disease and “Broken Windows”
por: Meléndez, Leo
Publicado: (2005)

Preventing Zika Virus Infection during Pregnancy Using a Seasonal Window of Opportunity for Conception
por: Martinez, Micaela Elvira
Publicado: (2016)

Integrative Oncology and the Clinical Care Network: Challenges and Opportunities
por: Semeniuk, George, et al.
Publicado: (2023)

Brain ischemia as a bridge to Alzheimer’s disease
por: Pluta, Ryszard
Publicado: (2021)

Rogue gene networks gone awry in Alzheimer's disease
por: Miyoshi, Emily, et al.
Publicado: (2021)

Precocious Alterations of Brain Oscillatory Activity in Alzheimer’s Disease: A Window of Opportunity for Early Diagnosis and Treatment
por: Hamm, Valentine, et al.
Publicado: (2015)

Discerning the Role of Blood Brain Barrier Dysfunction in Alzheimer’s Disease
por: Tao, Qing-Qing, et al.
Publicado: (2022)

Blood extracellular vesicles (EVs) of central nervous system origin: a window into the brain
por: Agliardi, Cristina, et al.
Publicado: (2019)

“Broken Windows”: Frumkin Responds
por: Frumkin, Howard
Publicado: (2005)

Integrating Early-Stage Drug Development with Clinical Networks; Challenges and Opportunities: The City of Hope Developing Experience
por: Villalona-Calero, Miguel A., et al.
Publicado: (2023)

Role of presynaptic calcium stores for neural network dysfunction in Alzheimer's disease
por: Lerdkrai, Chommanad, et al.
Publicado: (2018)

The new K(V)3.4 inhibitor BDS-I[1–8] as a potential pharmacological opportunity in Alzheimer’s disease therapy
por: Piccialli, Ilaria, et al.
Publicado: (2020)

Nose-to-brain drug delivery approach: a key to easily accessing the brain for the treatment of Alzheimer's disease
por: Alexander, Amit, et al.
Publicado: (2018)

Is blood-brain barrier a probable mediator of non-invasive brain stimulation effects on Alzheimer’s disease?
por: Petrovskaya, Aleksandra, et al.
Publicado: (2023)

The blood-brain barrier models to study apolipoprotein E genotypes in Alzheimer's disease
por: Dias, Irundika HK, et al.
Publicado: (2022)

The Golgi apparatus: Site for convergence of COVID-19 brain fog and Alzheimer’s disease?
por: Wang, Yanzhuang, et al.
Publicado: (2022)

Aquaporin 5 in Alzheimer’s disease: a link between oral and brain pathology?
por: Municio, Cristina, et al.
Publicado: (2022)

The brain compensatory mechanisms and Alzheimer's disease progression: a new protective strategy
por: Bobkova, Natalia, et al.
Publicado: (2015)

Protein condensation diseases: therapeutic opportunities
por: Vendruscolo, Michele, et al.
Publicado: (2022)

Ethical Principles, Constraints, and Opportunities in Clinical Proteomics
por: Mann, Sebastian Porsdam, et al.
Publicado: (2021)

Retinal Examination Modalities in the Early Detection of Alzheimer's Disease: Seeing Brain Through the Eye
por: Ma, Xiaoxi, et al.
Publicado: (2022)

Radio electric asymmetric brain stimulation in the treatment of behavioral and psychiatric symptoms in Alzheimer disease
por: Mannu, Piero, et al.
Publicado: (2011)

Brain insulin resistance: an early risk factor for Alzheimer's disease development in Down syndrome
por: Barone, Eugenio
Publicado: (2021)

Operationalizing selection criteria for clinical trials in Alzheimer's disease: Biomarker and clinical considerations
por: Petersen, Ronald C., et al.
Publicado: (2023)

The hidden variables problem in Alzheimer's disease clinical trial design
por: Liyanage, S. Imindu, et al.
Publicado: (2018)

An Overview of Experimental and Clinical Spinal Cord Findings in Alzheimer’s Disease
por: Xie, Qing, et al.
Publicado: (2019)

Recruiting to preclinical Alzheimer's disease clinical trials through registries
por: Grill, Joshua D.
Publicado: (2017)

Building clinically relevant outcomes across the Alzheimer's disease spectrum
por: Rentz, Dorene M., et al.
Publicado: (2021)

Window of Opportunity
Publicado: (1996)

Developing a Prognostic Model for Traumatic Brain Injury—A Missed Opportunity?
por: Young, Neil H, et al.
Publicado: (2008)

Neurorestoration from medicinal plants: an opportunity to treat painful neuropathies
por: Di Cesare Mannelli, Lorenzo, et al.
Publicado: (2017)

Challenges and Opportunities for Clinical Cytogenetics in the 21st Century
por: Heng, Eric, et al.
Publicado: (2023)

Spinal intradural electrodes: opportunities, challenges and translation to the clinic
por: Harland, Bruce, et al.
Publicado: (2023)

Inflammatory Bowel Disease in Asia: The Challenges and Opportunities
por: Hu, Pin-Jin
Publicado: (2015)

Preventative medicine and Alzheimer’s disease: is Alzheimer’s disease risk reduction achievable?
por: Sinyor, Benjamin, et al.
Publicado: (2021)

Desiccation tolerance: an unusual window into stress biology
por: Koshland, Douglas, et al.
Publicado: (2019)

Invited Perspective: PFAS and the Childhood Obesity Phenotype—Challenges and Opportunities
por: Stratakis, Nikos, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_lda0pno8nkla29m6p08qpde813